Publications by authors named "T V Latysheva"
Background: Over 40 years of use demonstrates that complement 1 esterase inhibitor (C1-INH) concentrate is effective and well tolerated for acute edema attacks and prophylaxis in patients with hereditary angioedema. OCTA-C1-INH is a new stable, virus-inactivated, nanofiltrated concentrate of C1-INH derived from human plasma.
Objective: We investigated the pharmacokinetics and safety profile of new C1-INH in people with hereditary angioedema during an attack-free period.
Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination.
Viruses
October 2023
Background: for the first time, the effect of one and two doses of adjuvanted influenza vaccines on toll-like receptors (TLRs) in patients with common variable immunodeficiency (CVID) was studied and compared (primary vaccination with one vs. two doses, primary vs. repeated vaccination).
View Article and Find Full Text PDFArticle Synopsis
- Deficiency of adenosine deaminase 2 (DADA2) leads to various health issues, like systemic vasculitis and red cell aplasia, but the reasons for these different manifestations are not fully understood.
- Researchers aimed to clarify the disease symptoms in DADA2 and understand how different ADA2 gene variants affect the disease.
- The study found that patients with DADA2 have similar inflammation-related gene expressions, and the analyzed ADA2 variants disrupt protein function through several mechanisms, contributing to the clinical diversity seen in patients.
Background: Severe acute respiratory syndrome corona virus (SARS-CoV-2) infection frequently causes severe and prolonged disease but only few specific treatments are available. We aimed to investigate safety and efficacy of a SARS-CoV-2-specific siRNA-peptide dendrimer formulation MIR 19® (siR-7-EM/KK-46) targeting a conserved sequence in known SARS-CoV-2 variants for treatment of COVID-19.
Methods: We conducted an open-label, randomized, controlled multicenter phase II trial (NCT05184127) evaluating safety and efficacy of inhaled siR-7-EM/KK-46 (3.
Article Synopsis
- The J Project (JP) is a collaborative program aimed at improving physician education and clinical research on inborn errors of immunity (IEI), established in 2004 and currently spanning 32 countries, primarily in Eastern and Central Europe.
- By the end of 2021, JP organized 344 meetings to enhance awareness and improve diagnosis and treatment for patients with IEI, with a significant increase in annual meetings over the years.
- Data from patient reports across 30 countries indicated a prevalence of 4.9 patients per population, mostly featuring patients with predominantly antibody deficiency, along with a strong commitment to treatments like immunoglobulin substitution and hematopoietic stem cell therapy.